NCT03369236View on ClinicalTrials.gov

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 12, 2018

Primary Completion Date

December 11, 2019

Study Completion Date

December 18, 2020

Conditions
C3 GlomerulopathyC3 GlomerulonephritisDense Deposit Disease
Interventions
DRUG

Danicopan

Danicopan was administered as an oral tablet.

DRUG

Placebo

Matching placebo was administered as an oral tablet.

Trial Locations (7)

10016

Clinical Study Site, New York

10032

Clinical Study Site, New York

21205

Clinical Study Site, Baltimore

30046

Clinical Study Site, Lawrenceville

52242

Clinical Study Site, Iowa City

80045

Clinical Study Site, Aurora

Unknown

Clinical Study Site, London

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY